This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

CME Academic Highlights

Reconsidering Insomnia as a Disorder Rather Than Just a Symptom in Psychiatric Practice

This Academic Highlights section of The Journal of Clinical Psychiatry presents the highlights of the planning teleconference series “Reconsidering Insomnia as a Disorder Rather Than Just a Symptom in Psychiatric Practice,” which was held in August and September 2017. This report was prepared and independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and was supported by an educational grant from Merck & Co., Inc.

The teleconference was chaired by Ruth M. Benca, MD, PhD, Department of Psychiatry and Human Behavior, University of California, Irvine. The faculty was Daniel J. Buysse, MD, from the Department of Psychiatry, University of Pittsburgh School of Medicine, Pennsylvania.

Financial Disclosure: All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past year, Marlene P. Freeman, MD, Editor in Chief, has received research funding from JayMac and Sage, has been a member of the Independent Data Safety and Monitoring Committee for Janssen, has been medical editor for the Global Organization for EPA and DHA Omega-3s newsletter, and, as a Massachusetts General Hospital (MGH) employee, works with the MGH National Pregnancy Registry, which is sponsored by Alkermes, Otsuka, Actavis, and Sunovion, and works with the MGH Clinical Trials Network and Institute, which receives research funding from multiple pharmaceutical companies and the National Institute of Mental Health. No member of the CME Institute staff reported any relevant personal financial relationships.

J Clin Psychiatry 2018;79(1):me17008ah1c

To cite: Benca RM, Buysse DJ. Reconsidering insomnia as a disorder rather than just a symptom in psychiatric practice. J Clin Psychiatry. 2018;79(1):me17008ah1c.

To share: https://doi.org/10.4088/JCP.me17008ah1c


This Academic Highlights summarizes a presentation given by Ruth M. Benca, MD, PhD, and Daniel J. Buysse, MD, both of whom are experts in insomnia. Together they discussed the need to reconsider insomnia as a comorbid condition rather than as a symptom of psychiatric disorders, as well as the diagnostic and treatment implications of this paradigm shift when managing patients with psychiatric disorders.

INSOMNIA AND PSYCHIATRIC DISORDERS: HOW ARE THEY CONNECTED?

Insomnia is an important consideration when evaluating patients with psychiatric disorders, because many of the symptoms of insomnia and psychiatric disorders overlap (Figure 1).1,2 Several of the most common psychiatric disorders include symptoms of irritability, depression, inattention, cognitive impairment, and fatigue.1 These symptoms are also associated with a number of sleep disorders.1,2 Furthermore, insomnia and mental illness are frequently comorbid, and some symptoms may be difficult to attribute to either insomnia or the mental health disorder alone.1,3 Roth and colleagues3 analyzed data from the National Comorbidity Survey Replication (NCS-R) and found that sleep problems were significantly associated with DSM-IV4 anxiety, mood, impulse-control, and substance disorders (odds ratio for association of any insomnia symptom with any psychiatric disorder = 4.1), and the likelihood of having sleep problems increased with the number of DSM-IV diagnoses.3 Study participants also reported substantial role impairment that persisted after controlling for comorbid mental disorders, thus indicating that at least some of these patients’ impairment was due exclusively to the effect of their sleep problems.3

ASSESSMENT OF INSOMNIA IN PATIENTS WITH PSYCHIATRIC DISORDERS

The current diagnostic criteria for insomnia according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5),1 state that an individual should be diagnosed with insomnia if he or she experiences dissatisfaction with quantity or quality of sleep associated with difficulty initiating or maintaining sleep or with early morning awakening with the inability to return to sleep. This sleep difficulty must occur at least 3 nights per week for at least 3 months, despite adequate opportunity for sleep, and the individual must experience clinically significant distress or impairment as a result. The patient’s symptoms cannot be attributable to the direct physiologic effects of a substance or be better explained by another sleep-wake disorder.

Figure 1

Click figure to enlarge

An important change in the DSM-5 is that rather than conceiving of insomnia as primary or secondary as previous criteria specified,5 an insomnia diagnosis now simply includes a specifier to indicate the presence of a comorbidity, including medical, mental, or other sleep disorders.1 As a result of this shift, insomnia is now considered a comorbid disorder that should be a separate focus of treatment, because in patients who have both a psychiatric disorder and insomnia, the insomnia may not necessarily improve as a result of treatment for the psychiatric disorder.

Another important implication of the shift in DSM-5 is that it removes any assignment of causality. A mental disorder can contribute to insomnia or vice versa. The key point is that insomnia and psychiatric disorders are strongly related and should be considered risk factors for each other.3 For example, Furihata and colleagues6 assessed more than 6,000 older women and found that the greater the number of sleep dimensions reported as poor, the greater the likelihood of experiencing depression, both cross-sectionally and longitudinally.

In addition to using the DSM-5 criteria to diagnose insomnia, the clinical assessment of patients with insomnia and psychiatric disorders should consist of a thorough clinical history including the following information:

  • the patient’s sleep-related behaviors and use of substances that might affect sleep;
  • the times at which the patient goes to bed, actually attempts to go to sleep, wakes up, and gets out of bed;
  • the quantity of sleep the patient obtains;
  • variations in the patient’s sleep schedule due to weekends or time off;
  • any daytime symptoms, including fatigue, mood symptoms, and cognitive or functional impairments, as well as napping behaviors;
  • social, economic, or occupational stressors that may be creating anxiety that contributes to sleep difficulties;
  • the duration and chronology of the patient’s sleep difficulties, as well as response to any previous treatment trials; and
  • assessment for other sleep symptoms and disorders, including sleep apnea, restless legs syndrome, parasomnias, and circadian rhythm disorders.7

It is important to emphasize that the patient evaluation should be based on a 24-hour history and the focus should be on daytime functioning as well as the amount of sleep obtained during the night.

TREATING INSOMNIA IN PATIENTS WITH PSYCHIATRIC DISORDERS

The treatment of insomnia in patients with psychiatric disorders can include both pharmacologic and behavioral interventions. Although individuals with insomnia tend to rely heavily on sleep medications, current practice guidelines8 recommend that all adults with chronic insomnia disorder receive cognitive-behavioral therapy for insomnia (CBT-I) as their initial treatment. If CBT-I alone is unsuccessful, a shared decision-making approach should be implemented to determine if pharmacotherapy should be added.

clinical points
  • Assess patients with psychiatric disorders and sleep difficulties for a comorbid insomnia disorder
  • Attempt initial behavioral therapy for all patients with comorbid psychiatric disorders and insomnia
  • For patients whose insomnia does not fully remit following behavioral treatment, consider adding a pharmacologic treatment
  • Select pharmacotherapy for insomnia based on the nature of the patient’s insomnia, individual patient characteristics and preferences, and the presence of any comorbidities

Behavioral Treatments

Numerous behavioral techniques have been explored for the treatment of insomnia, including CBT-I, sleep hygiene education, stimulus control, sleep restriction, and relaxation training, among others,9 but a shortage of trained providers exists,10 and the demand for these services, therefore, greatly exceeds the supply.

To understand behavioral treatments, it is helpful to consider them in relation to how the brain controls sleep and wakefulness—through the homeostatic sleep drive that builds up with time awake and the endogenous circadian rhythm; the different mechanisms can be conceived of as an hourglass, a clock, and an alarm.11 The hourglass monitors the body’s duration of wakefulness, the clock regulates sleep and wake times over a 24-hour day, and the alarm influences momentary levels of arousal. Different types of behavioral treatments can be understood in terms of which part of the process they target.

Dr Buysse and his colleagues at the University of Pittsburgh School of Medicine developed a simplified version of CBT-I called Brief Behavioral Treatment for Insomnia (BBTI), which consists of 4 behavioral recommendations that can easily be implemented in primary or psychiatric practice.12 The components of BBTI are designed to address the body’s hourglass, clock, and alarm mechanisms, and include the following instructions:

  1. Reduce time in bed
  2. Wake up at the same time every day, regardless of sleep duration
  3. Do not go to bed until sleepy
  4. Do not stay in bed unless asleep

In this study,12 the participants who received BBTI showed significantly greater improvement in multiple sleep domains compared with the control group (P < .001). Thus, BBTI is an effective and practical intervention that is easy to administer. Patients who do not have access to other forms of behavioral treatment may benefit from web-based CBT-I programs that are available and have been found to be effective.13

Pharmacologic Treatments

The use of prescription agents to treat insomnia has increased considerably in recent years.14 This includes both US Food and Drug Administration (FDA)-approved and off-label prescribing. In addition, many individuals rely on over-the-counter treatments or substances such as alcohol to manage their insomnia.15 Polypharmacy is common14 and may increase the risk of drug-drug interactions in patients who are already taking pharmacotherapies for psychiatric disorders. Practice guidelines16,17 from the American Academy of Sleep Medicine (AASM) recommend that treatments be selected based on characteristics of the patient’s insomnia, comorbidities, and patient preference.

Over-the-counter agents. Many individuals with insomnia do not consult their health care providers about their sleep difficulties and rely instead on over-the-counter medications.15 These medications include antihistamines, melatonin, and valerian; however, there are few studies assessing their use in insomnia, and the data that are available suggest that they have not been found to be particularly effective for insomnia.17,18

The over-the-counter antihistamines diphenhydramine and doxylamine are commonly taken for insomnia. Available evidence from clinical trials is poor, and common side effects include drowsiness and grogginess.17 This hangover effect can persist for up to 12 hours after administration of the agent.19 Another problem is that people tend to use these agents routinely for insomnia, but tolerance to the sedative effects of antihistamines such as diphenhydramine has been found to develop quite quickly, in some cases after just 3 days.20

Melatonin is available as an over-the-counter supplement in a variety of dosages, and the dose used in clinical trials has varied considerably.18 Regardless of the dose used, however, studies have found that melatonin use is associated with only small and not clinically significant improvements in sleep latency, total sleep time, and sleep efficiency.17 However, melatonin may be helpful in patients whose insomnia complaints relate to problems with circadian rhythm entrainment.

FDA-approved agents. A variety of medications have been approved for the treatment of insomnia (Table 1).17,18,21 Although practice guidelines can assist in the selection of insomnia treatments, special consideration should be given for patients with comorbid psychiatric disorders.17,18

Table 1

Click figure to enlarge

The benzodiazepines that are FDA-approved for the treatment of insomnia include temazepam, triazolam, flurazepam, estazolam, and quazepam, but current practice guidelines17 recommend only temazepam and triazolam. The other 3 approved benzodiazepines have inadequate data as well as longer half-lives that increase the risk of a next-day hangover effect and can lead to the agent building up in the patient’s system with chronic use. Benzodiazepines increase sleep by binding to GABA-A receptors, but because these receptors are found throughout the brain, benzodiazepines have additional effects. Some of these, such as anxiolytic and myorelaxant effects, may be beneficial to patients, but others, such as cognitive and motor impairment, are considered adverse effects. Furthermore, because of their effect on reward circuits, benzodiazepines have the potential for abuse.18 Temazepam is recommended for sleep onset and sleep maintenance insomnia; triazolam is recommended for sleep onset insomnia.17

Benzodiazepine receptor agonists (BZRAs) are the most commonly used prescription agents for the treatment of insomnia.17 Agents in this class that are FDA-approved for the treatment of insomnia include zolpidem (both immediate- and extended-release formulations), zaleplon, and eszopiclone. Like benzodiazepines, these agents bind to GABA-A receptors, but they do so more selectively, and they have shorter half-lives, which makes them effective for insomnia with fewer next-day effects.18 Eszopiclone and the extended-release formulation of zolpidem have longer durations of action and are effective for sleep maintenance as well as sleep onset insomnia. BZRAs do have a risk for abuse, and next-day sedation may occur with the longer-acting agents.18 Other adverse effects associated with BZRAs include tolerance and rebound insomnia following abrupt discontinuation. These agents have also been associated with complex sleep-related behaviors, or parasomnias, such as sleep eating, sleep walking, and sleep driving.22,23 Although these types of sleep-related behaviors are infrequent, they are potentially serious, and patients with comorbid psychiatric disorders may be at an increased risk of experiencing these adverse events.22,23

The melatonin receptor agonist ramelteon has a short half-life, from 1 to 3 hours, which makes it an appropriate treatment for sleep onset insomnia but with little effect on sleep maintenance.18 Ramelteon has a favorable side effect profile with no evidence of abuse or dependence potential.17,18

Suvorexant is thought to alleviate insomnia by binding to the orexin receptor types 1 and 2, which are located in the regions of the brain that promote arousal and vigilance.24 Suvorexant has been found to decrease sleep latency and wake after sleep onset, increasing total sleep time.25 No withdrawal effects have been observed following discontinuation from this treatment, but it carries a risk for side effects similar to other hypnotic agents, such as complex sleep-related behaviors and sleepiness during the day.25 Additional side effects, although rare, can include temporary sleep paralysis upon falling asleep or waking up or temporary weakness in the legs. Patients who have narcolepsy should not take suvorexant.

The tricyclic antidepressant doxepin is also an FDA-approved treatment for insomnia, albeit at a much lower dose than used for depression. Although doxepin is an antidepressant at doses of 75 to 150 mg/d, as an insomnia treatment, a dose of only 3 to 6 mg/d is used18; at this low dose, doxepin acts primarily as a selective antagonist of H1 histamine receptors in the brain. Doxepin is effective for the treatment of sleep maintenance insomnia and at the low hypnotic dose has not been found to be associated with any serious adverse events or residual next-day effects.17,18

Off-label agents. The prescription medications most commonly used off-label to treat insomnia are sedating antidepressants, anticonvulsants, and second-generation antipsychotics. Antidepressants are a particularly popular treatment option in patients with psychiatric disorders and insomnia, because clinicians hope to treat both conditions with one agent. In fact, trazodone is one of the most frequently prescribed insomnia treatments,18 although unfortunately the hypnotic dose is well below that recommended for depression. As a result, trazodone is frequently an add-on therapy to other antidepressant medications. Sedating antidepressants, such as mirtazapine, tricyclics, and trazodone, are thought to combat insomnia through antagonism of wake-promoting systems such as serotonin, norepinephrine, acetylcholine, and histamine.18 However, no evidence is available to support the effectiveness of antidepressants for insomnia, and they can potentially cause numerous side effects, including sedation, weight gain, anticholinergic symptoms, and cardiotoxicity.17,18 In addition, certain antidepressants, such as bupropion and desvenlafaxine,26 are known to have activating properties and should be avoided if possible in patients with sleep difficulties.

Anticonvulsants that are sometimes used to treat insomnia include gabapentin, pregabalin, and tiagabine. The first two are thought to decrease insomnia by decreasing the activity of wake-promoting glutamate and norepinephrine systems, whereas tiagabine promotes sleep by inhibiting the reuptake of GABA.18 Gabapentin and pregabalin have been found to enhance slow-wave sleep and to reduce sleep disturbance in patients with pain-related disorders.27 Furthermore, these agents have a low potential for abuse, although they can be associated with next-day sedation and cognitive impairment. Although they may be helpful for sleep in patients with chronic pain syndromes,28 there are few data on their efficacy for insomnia.18

Second-generation antipsychotics that are frequently used for insomnia are quetiapine, olanzapine, and risperidone. These agents promote sleep through antagonism of dopamine, histamine, serotonin, acetylcholine, and norepinephrine.18 Second-generation antipsychotics may be appealing treatment options for insomnia in patients with psychiatric disorders because of their low potential for abuse and their ability to treat anxiety, psychosis, and mood disorders. However, clinicians need to keep in mind the well-known side effects of second-generation antipsychotics, such as weight gain, risk of movement abnormalities, and metabolic syndrome.

Case Practice Question

Case 1. Sue is a 57-year-old married woman who is an artist with 2 adult children. She has a history of depression, with several previous episodes that lasted for weeks to months at a time, but she has generally functioned well with pharmacotherapy and supportive psychotherapy. She is physically healthy and has no history of substance use.

Sue presents with insomnia symptoms that have been increasing over the past month and depressive symptoms that have been increasing over the past 2 weeks. Her sleep started to worsen as she began to feel the stress from preparing for her son’s wedding. She initially had difficulty falling asleep, sometimes taking as long as 90 minutes, and then she began awakening frequently during the night. To compensate, she tried going to bed earlier. She now goes to bed around 10:00 pm and stays in bed until 7:00 am, and later on weekends, but still reports only 6 to 7 hours of total sleep. Her depressive symptoms have worsened along with her sleep difficulties. She reports reduced daytime energy, difficulty concentrating, and apathy. Her depressive episodes often follow a seasonal pattern, getting worse during winter months. In the past, her episodes of depression have been accompanied by insomnia, but she has also experienced insomnia in the absence of depressive symptoms but during stressful periods. Sue is currently taking 300 mg/d of extended release bupropion for depression and 25 to 50 mg/d of diphenhydramine at bedtime as needed, with variable success.

What is the best option for addressing Sue’s insomnia?

  1. Prescribe a short-term BZRA to help her get through this stressful period and then see if symptoms remit
  2. Switch Sue from bupropion to a less activating antidepressant
  3. Begin behavioral treatments such as reducing time in bed and maintaining a regular sleep-wake schedule
  4. a and c
  5. b and c

Discussion of Case Practice Question

Preferred response: e. Both b and c

Explanation: Sue is currently experiencing a major depressive episode with significant insomnia symptoms, despite current treatment with bupropion. Because the bupropion is not effectively treating her depression and may be exacerbating her insomnia,26 a reasonable option would be to switch her to an antidepressant less associated with sleep disturbance. She should also be advised to spend less time in bed in order to enhance her homeostatic sleep drive, and to avoid oversleeping on weekends.

Case Practice Question

Case 2. Summer is a 24-year-old white woman who worked as a sales clerk and had her own apartment, but she recently lost her job, got evicted, and is now staying with friends. Summer has a history of posttraumatic stress disorder (PTSD) stemming from being repeatedly sexually abused by her mother’s boyfriend when she was a teenager. He would come into her room after her mother had gone to bed. She had never been a good sleeper, and once the abuse started, she developed fears of going to bed, difficulty falling asleep and staying asleep, and nightmares. During adolescence, she began experiencing depression and was hospitalized twice for suicide attempts. She was treated with a selective serotonin reuptake inhibitor (SSRI), which improved her mood but not her insomnia or nightmares, so she discontinued treatment. She began to use marijuana and abuse alcohol as a teenager to help manage her PTSD symptoms. More recently, she was prescribed 1 mg of alprazolam, 4 times a day, which she said helped, yet her previous psychiatrist abruptly discontinued this for unknown reasons.

Summer presents to the clinic to establish care with a new clinician. Her mood has worsened since losing her job and she fears becoming suicidal. Her insomnia symptoms have also worsened and her nightmares have increased. She sleeps with a light on at all times. She says her current sleep pattern is to try to go to bed around 10:00 pm, but she lies in bed feeling anxious and fearful. Then, she gets up, smokes marijuana and has a couple drinks of liquor, and usually falls asleep for a couple hours before she is awakened by a nightmare and has difficulty getting back to sleep. She wakes up between 5:00 am and 6:00 am and tries to go back to sleep, usually unsuccessfully, and gets out of bed around 7:00 am, having only gotten about 5 hours of sleep total.

Which of the following should NOT be a component of Summer’s treatment plan?

  1. Because of her positive experience with alprazolam, prescribe a benzodiazepine to be taken before bed
  2. Begin treatment with an SSRI to alleviate the symptoms of PTSD, which should be beneficial for her insomnia and nightmares
  3. Recommend behavioral treatments, including improving sleep hygiene, reducing time in bed, and maintaining low light during sleep time
  4. Initiate substance abuse treatment to address her marijuana use and binge drinking because alcohol is known to contribute to poor sleep maintenance

Discussion of Case Practice Question

Preferred response: a. Because of her positive experience with alprazolam, prescribe a benzodiazepine or BZRA to be taken before bed

Explanation: Since Summer has been binge drinking and using marijuana, she should not be prescribed a sleep aid with a potential for abuse such as a benzodiazepine or BZRA. Her treatment should include assessment and treatment of depression and substance use and behavioral therapy promoting more effective sleep routines.

Published online: January 23, 2018.

 

This CME activity is expired. For more CME activities, visit cme.psychiatrist.com.
Find more articles on this and other psychiatry and CNS topics:
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

 

REFERENCES

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. Washington, DC: American Psychiatric Publishing; 2013.

2. Palmer CA, Alfano CA. Sleep and emotion regulation: an organizing, integrative review. Sleep Med Rev. 2017;31:6-16. PubMed CrossRef

3. Roth T, Jaeger S, Jin R, et al. Sleep problems, comorbid mental disorders, and role functioning in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry. 2006;60(12):1364-1371. PubMed CrossRef

4. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders. Fourth Edition (DSM-IV). Washington, DC: American Psychiatric Association; 1994.

5. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders. Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.

6. Furihata R, Hall MH, Stone KL, et al. An aggregate measure of sleep health is associated with prevalent and incident clinically significant depression symptoms among community-dwelling older women. Sleep. 2017;40(3). PubMed CrossRef

7. Buysse DJ. Insomnia. JAMA. 2013;309(7):706-716. PubMed CrossRef

8. Qaseem A, Kansagara D, Forciea MA, et al; Clinical Guidelines Committee of the American College of Physicians. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125. PubMed CrossRef

9. Brasure M, Fuchs E, MacDonald R, et al. Psychological and behavioral interventions for managing insomnia disorder: an evidence report for a clinical practice guideline by the American College of Physicians. Ann Intern Med. 2016;165(2):113. PubMed CrossRef

10. Thomas A, Grandner M, Nowakowski S, et al. Where are the behavioral sleep medicine providers and where are they needed? a geographic assessment. Behav Sleep Med. 2016;14(6):687-698. PubMed CrossRef

11. Cajochen C, Chellappa S, Schmidt C. What keeps us awake? the role of clocks and hourglasses, light, and melatonin. Int Rev Neurobiol. 2010;93:57-90. PubMed CrossRef

12. Buysse DJ. Efficacy of brief behavioral treatment for chronic insomnia in older adults. Arch Intern Med. 2011;171(10):887. PubMed CrossRef

13. Ritterband LM, Thorndike FP, Ingersoll KS, et al. Effect of a web-based cognitive behavior therapy for insomnia intervention with 1-year follow-up: a randomized clinical trial. JAMA Psychiatry. 2017;74(1):68-75. PubMed CrossRef

14. Bertisch SM, Herzig SJ, Winkelman JW, et al. National use of prescription medications for insomnia: NHANES 1999-2010. Sleep. 2014;37(2):343-349. PubMed CrossRef

15. Fuller JM, Wong KK, Hoyos C, et al. Dispensing good sleep health behaviours not pills: a cluster-randomized controlled trial to test the feasibility and efficacy of pharmacist-provided brief behavioural treatment for insomnia. J Sleep Res. 2016;25(1):104-115. PubMed CrossRef

16. Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487-504. PubMed

17. Sateia MJ, Buysse DJ, Krystal AD. Clinical practice guideline for the evaluation and management of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307-349. PubMed CrossRef

18. Minkel J, Krystal AD. Optimizing the pharmacologic treatment of insomnia. Sleep Med Clin. 2013;8(3):333-350. PubMed CrossRef

19. Zhang D, Tashiro M, Shibuya K, et al. Next-day residual sedative effect after nighttime administration of an over-the-counter antihistamine sleep aid, diphenhydramine, measured by positron emission tomography. J Clin Psychopharmacol. 2010;30(6):694-701. PubMed CrossRef

20. Richardson GS, Roehrs TA, Rosenthal L, et al. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol. 2002;22(5):511-515. PubMed CrossRef

21. Stahl SM. Prescriber’s Guide. S.L. New York, NY: Cambridge University Press; 2017.

22. Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours : incidence, mechanisms and management. CNS Drugs. 2008;22(12):1021-1036. PubMed CrossRef

23. Lam SP, Fong SYY, Ho CKW, et al. Parasomnia among psychiatric outpatients: a clinical, epidemiologic, cross-sectional study. J Clin Psychiatry. 2008;69(9):1374-1382. PubMed CrossRef

24. Norman JL, Anderson SL. Novel class of medications, orexin receptor antagonists, in the treatment of insomnia: critical appraisal of suvorexant. Nat Sci Sleep. 2016;8:239-247. PubMed CrossRef

25. Wilt TJ, MacDonald R, Brasure M, et al. Pharmacologic treatment of insomnia disorder: an evidence report for a clinical practice guideline by the American College of Physicians. Ann Intern Med. 2016;165(2):103. PubMed CrossRef

26. Alberti S, Chiesa A, Andrisano C, et al. Insomnia and somnolence associated with second-generation antidepressants during the treatment of major depression: a meta-analysis. J Clin Psychopharmacol. 2015;35(3):296-303. PubMed CrossRef

27. McCall C, McCall WV. What is the role of sedating antidepressants, antipsychotics, and anticonvulsants in the management of insomnia? Curr Psychiatry Rep. 2012;14(5):494-502. PubMed CrossRef

28. Russell IJ, Crofford LJ, Leon T, et al. The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome. Sleep Med. 2009;10(6):604-610. PubMed CrossRef

Related Articles

Volume: 79

Quick Links: Sleep-Wake

References